# Primary Biliary Cholangitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/primary-biliary-cholangitis

> 4 upcoming FDA catalysts in primary Biliary Cholangitis: Livdelzi® (seladelpar, GILD) on December 2028 (primary completion); Livdelzi® (seladelpar, GILD) on Dec 2028 to Mar 2029 (topline data readout); Livdelzi® (seladelpar, GILD) on August 2030 (primary completion); Livdelzi® (seladelpar, GILD) on Aug to Nov 2030 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 6, 2026 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | completed | "NCT06060665 (Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-06 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06060665)) |
| December 2028 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT07841977 (Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841977)) |
| Dec 2028 to Mar 2029 | [Livdelzi® (seladelpar) topline data readout](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT07841977 (Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07841977)) |
| August 2030 | [Livdelzi® (seladelpar) primary completion](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT06051617 (Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051617)) |
| Aug to Nov 2030 | [Livdelzi® (seladelpar) topline data readout](https://sec-api.dev/pdufa/seladelpar) | GILD | Primary Biliary Cholangitis | scheduled | "NCT06051617 (Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051617)) |

## Drugs

- [Livdelzi® (seladelpar)](https://sec-api.dev/pdufa/seladelpar) (GILD)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/primary-biliary-cholangitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Primary Biliary Cholangitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/primary-biliary-cholangitis

```bibtex
@misc{secapidev_indications_primary_biliary_cholangitis_20261116,
  title        = {Primary Biliary Cholangitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/primary-biliary-cholangitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_primary_biliary_cholangitis_20261116","title":"Primary Biliary Cholangitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/primary-biliary-cholangitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
